A- A A+

EASL Recommendations on Treatment of Hepatitis C 2018

Pawlotsky, Jean-Michel et al.

Journal of Hepatology , Volume 0 , Issue 0 , doi.org/10.1016/j.jhep.2018.03.026


A sofosbuvir-based quadruple regimen is highly effective in HCV type 4-infected Egyptian patients with DAA treatment failure

Abdel-Moneim, Adel et al.

Journal of Hepatology , Volume 0 , Issue 0 , doi.org/10.1016/j.jhep.2018.03.010


Activity of alcohol dehydrogenase isoenzymes and aldehyde dehydrogenase in sera of patients with hepatitis C.

Jelski W, Strumnik A, Orywal K, Lapinski TW, Swiderska M, Szmitkowski M.

Arch Med Sci. 2018 Mar;14(2):281-287. doi: 10.5114/aoms.2016.60406.


Kombination heilt Hepatitis C für weniger als 300 US-Dollar

Paris – Eine erfolgreiche Behandlung der Hepatitis C muss kein Vermögen kosten. Die Kombination aus Ravidasvir und Sofosbuvir erzielte nach den jetzt auf der International Liver Conference in Paris vorgestellten Studienergebnissen in Malaysia und Thailand eine Heilungsrate von 97 %. Die 12-wöchige Therapie kostete etwa 300 US-Dollar. Das ist weniger als die hiesigen Krankenkassen für eine einzige Tablette ausgeben müssten. (aerzteblatt.de, 13.04.2018)


Transmission genetics of drug-resistant hepatitis C virus.

van Buuren N, Tellinghuisen TL, Richardson CC, Kirkegaard K.

Elife. 2018 Mar 28;7. pii: e32579. doi: 10.7554/eLife.32579.


Linkage to care specialist facilitates access to hepatitis C treatment for people who inject drugs

A prospective, longitudinal study involving more than 1,000 people who inject drugs has identified a promising role for linkage to care specialists in facilitating rapid access to hepatitis C treatment. The study, which was conducted in Texas, USA, ensured that individuals newly diagnosed with hepatitis C were contacted by a linkage to care specialist within 48 hours of being referred to the service, thereby ensuring that almost 50% of patients referred to a medical practitioner made it to their first appointment and that 60% of those seen were initiated on treatment.

(European Association for the Study of the Liver, 12.04.2018)


Post-treatment alpha fetoprotein and platelets predict hepatocellular carcinoma development in dual-infected hepatitis B and C patients after eradication of hepatitis C.

Yeh ML, Huang CI, Huang CF, Hsieh MH, Hsieh MY, Lin ZY, Chen SC, Huang JF, Kuo PL, Kuo HT, Dai CY, Yu ML, Chuang WL.

Oncotarget. 2018 Jan 13;9(15):12240-12249. doi: 10.18632/oncotarget.24219.


Infektiologen entwickeln therapeutischen Impfstoff gegen Hepatitis B

Braunschweig – Einen neuen therapeutischen Impfstoff gegen eine Hepatitis-B-Infektion haben Wissenschaftler am Deutschen Zentrum für Infektionsforschung (DZIF) in Braunschweig entwickelt. Dieser soll nun in die klinische Prüfung gehen. Obwohl es einen wirksamen Impfstoff gegen Hepatitis B gibt, leiden weltweit rund 260 Millionen Menschen unter einer chronischen Hepatitis B, die derzeit nicht heilbar ist. Jedes Jahr sterben etwa 880.000 Menschen an den Folgen der Infektion. (aerzteblatt.de, 12.04.2018)


Access to Hepatitis C treatment: lessons from implementation of strategies for increasing access to antiretroviral treatment.

Assefa Y, Hill PS, Williams OD.

Int J Infect Dis. 2018 Mar 14. pii: S1201-9712(18)30063-8. doi: 10.1016/j.ijid.2018.03.004.


Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial

Grebely, Jason et al.

The Lancet Gastroenterology & Hepatology , Volume 3 , Issue 3 , 153 - 161



Epidemiology of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Related Hepatocellular Carcinoma.

Petruzziello A.

Open Virol J. 2018 Feb 28;12:26-32. doi: 10.2174/1874357901812010026.


Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in a real-world setting.

Höner Zu Siederdissen C, Buggisch P, Böker K, Schott E, Klinker H, Pathil A, Pfeiffer-Vornkahl H, Berg T, Sarrazin C, Hüppe D, Manns MP, Mauss S.

United European Gastroenterol J. 2018 Mar;6(2):213-224. doi: 10.1177/2050640617716607.


Hepatitis C Virus and Hepatocellular Carcinoma: Pathogenetic Mechanisms and Impact of Direct-Acting Antivirals.

Schietroma I, Scheri GC, Pinacchio C, Statzu M, Petruzziello A, Vullo V.

Open Virol J. 2018 Feb 28;12:16-25. doi: 10.2174/1874357901812010016.


Management of drug interactions with direct-acting antivirals in Dutch HIV/hepatitis C virus-coinfected patients: adequate but not perfect.

Smolders EJ, Smit C, de Kanter C, Dofferhoff A, Arends JE, Brinkman K, Rijnders B, van der Valk M, Reiss P, Burger DM; ATHENA National HIV Observational Cohort.

HIV Med. 2018 Mar;19(3):216-226. doi: 10.1111/hiv.12570.


Impact of direct acting antivirals on occurrence and recurrence of hepatocellular carcinoma: Biologically plausible or an epiphenomenon?

Butt AS, Sharif F, Abid S.

World J Hepatol. 2018 Feb 27;10(2):267-276. doi: 10.4254/wjh.v10.i2.267. Review.


Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection.

Wei L, Wang FS, Zhang MX, Jia JD, Yakovlev AA, Xie W, Burnevich E, Niu JQ, Jung YJ, Jiang XJ, Xu M, Chen XY, Xie Q, Li J, Hou JL, Tang H, Dou XG, Gandhi Y, Hu WH, McPhee F, Noviello S, Treitel M, Mo L, Deng J.

World J Gastroenterol. 2018 Mar 28;24(12):1361-1372. doi: 10.3748/wjg.v24.i12.1361.


Optimization of direct anti-viral agent treatment schedule: Focus on HCV genotype 3.

Morisco F, Granata R, Camera S, Ippolito A, Milella M, Conti F, Masetti C, Smedile A, Tundo P, Santantonio T, Valvano MR, Termite A, Gatti P, Messina V, Iacobellis A, Librandi M, Caporaso N, Andriulli A; ITAL-C consortium.

United European Gastroenterol J. 2018 Mar;6(2):225-237. doi: 10.1177/2050640617717158.


Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus.

Rupp C, Hippchen T, Neuberger M, Sauer P, Pfeiffenberger J, Stremmel W, Gotthardt DN, Mehrabi A, Weiss KH.

World J Gastroenterol. 2018 Mar 28;24(12):1353-1360. doi: 10.3748/wjg.v24.i12.1353.


Vitamin D deficiency is a risk factor for infections in patients affected by HCV-related liver cirrhosis.

Buonomo AR, Zappulo E, Scotto R, Pinchera B, Perruolo G, Formisano P, Borgia G, Gentile I.

Int J Infect Dis. 2017 Oct;63:23-29. doi: 10.1016/j.ijid.2017.07.026.


Potential geographic "hotspots" for drug-injection related transmission of HIV and HCV and for initiation into injecting drug use in New York City, 2011-2015, with implications for the current opioid epidemic in the US.

Des Jarlais DC, Cooper HLF, Arasteh K, Feelemyer J, McKnight C, Ross Z (2018)

PLoS ONE 13(3): e0194799. https://doi.org/10.1371/journal.pone.0194799


Sofosbuvir and daclatasvir.

Hessel MH, Cohen AF, Rissmann R.

Br J Clin Pharmacol. 2016 Sep;82(3):878-9. doi: 10.1111/bcp.13011.


Intervention Packages to Reduce the Impact of HIV and HCV Infections Among People Who Inject Drugs in Eastern Europe and Central Asia: A Modeling and Cost-effectiveness Study.

Mabileau G, Scutelniciuc O, Tsereteli M, Konorazov I, Yelizaryeva A, Popovici S, Saifuddin K, Losina E, Manova M, Saldanha V, Malkin JE, Yazdanpanah Y.

Open Forum Infect Dis. 2018 Feb 17;5(3):ofy040. doi: 10.1093/ofid/ofy040.